Literature DB >> 26010063

Epidemiology and economic burden of asthma.

Patricia A Loftus1, Sarah K Wise1.   

Abstract

BACKGROUND: The "asthma epidemic" is on the rise, with the Center for Disease Control (CDC) epidemiological studies reporting a 3.0% asthma prevalence in the United States in 1970, 5.5% in 1996, and 7.8% in 2006 to 2008. This results in an immense economic burden, with asthma costing an estimated $56 billion in the United States in 2007, which is a 6% increase from the $53 billion that was spent in 2002.
METHODS: A review of the current literature and CDC reports were used to thoroughly examine and summarize the epidemiology and economic burden of asthma domestically and globally.
RESULTS: Asthma shows a male predominance before puberty, and a female predominance in adulthood. Studies show Puerto Ricans to be the most commonly affected ethnicity, and a higher prevalence of asthma is found in lower income populations. Asthma is related to some of the more common otolaryngologic diseases such as allergy and obstructive sleep apnea. The condition results in significant morbidity, such as an increase in emergency department visits and a decrease in productivity due to missed school and works days.
CONCLUSION: Epidemiological statistics report an undisputable increase of asthma both domestically and worldwide, which means the economic burden of this disease is also on the rise. Better access to healthcare, improved asthma education, and bridging the gap between ethnic and racial disparities in the treatment and management of asthma may help to control this epidemic, promote better outcomes, and prevent continued rising costs related to the management of this widespread disease.
© 2015 ARS-AAOA, LLC.

Entities:  

Keywords:  allergy; asthma; economic burden; epidemiology; pediatrics

Mesh:

Year:  2015        PMID: 26010063     DOI: 10.1002/alr.21547

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  34 in total

Review 1.  Vitamin D and Bronchial Asthma: An Overview of Data From the Past 5 Years.

Authors:  Sannette C Hall; Devendra K Agrawal
Journal:  Clin Ther       Date:  2017-04-25       Impact factor: 3.393

Review 2.  Pathogenic CD4+ T cells in patients with asthma.

Authors:  Lyndsey M Muehling; Monica G Lawrence; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2017-04-22       Impact factor: 10.793

3.  Improving Patient-Provider Communication and Therapeutic Practice Through Better Integration of Electronic Health Records in the Exam Room: A Pilot Study.

Authors:  Minal R Patel; Alyssa Smith; Harvey Leo; Wei Hao; Kai Zheng
Journal:  Health Educ Behav       Date:  2018-09-08

Review 4.  Airway Microbiota and the Implications of Dysbiosis in Asthma.

Authors:  Juliana Durack; Homer A Boushey; Susan V Lynch
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

5.  A Statewide Study of the Epidemiology of Emergency Medical Services' Management of Pediatric Asthma.

Authors:  Jennifer N Fishe; Eugene Palmer; Erik Finlay; Carmen Smotherman; Shiva Gautam; Phyllis Hendry; Leslie Hendeles
Journal:  Pediatr Emerg Care       Date:  2019-02-14       Impact factor: 1.454

6.  Selective cleavage of fibrinogen by diverse proteinases initiates innate allergic and antifungal immunity through CD11b.

Authors:  Cameron T Landers; Hui-Ying Tung; J Morgan Knight; Matthew C Madison; Yifan Wu; Zhimin Zeng; Paul C Porter; Antony Rodriguez; Matthew J Flick; Farrah Kheradmand; David B Corry
Journal:  J Biol Chem       Date:  2019-04-16       Impact factor: 5.157

7.  Racial and Ethnic Disparities in Acute Care Use for Pediatric Asthma.

Authors:  Jorge Kaufmann; Miguel Marino; Jennifer Lucas; Steffani R Bailey; Sophia Giebultowicz; Jon Puro; David Ezekiel-Herrera; Shakira F Suglia; John Heintzman
Journal:  Ann Fam Med       Date:  2022 Mar-Apr       Impact factor: 5.166

8.  Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.

Authors:  Carlos E Rodriguez-Martinez; Monica P Sossa-Briceño; Jose A Castro-Rodriguez
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

Review 9.  Asthma biologics: Comparing trial designs, patient cohorts and study results.

Authors:  Ali Doroudchi; Mohini Pathria; Brian D Modena
Journal:  Ann Allergy Asthma Immunol       Date:  2019-10-23       Impact factor: 6.347

10.  Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma.

Authors:  Lingna Xue; Cui Li; Guangbo Ge; Shaoyan Zhang; Liming Tian; Yu Wang; Huiyong Zhang; Zifeng Ma; Zhenhui Lu
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.